Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2024 it was $177.96M.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $177.96M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $11.18M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $6.41M | – |
See a number that looks wrong?